Forte Biosciences, Inc. (FBRX)
17.19
+0.37
(+2.20%)
USD |
NASDAQ |
Jun 11, 10:43
Forte Biosciences Enterprise Value : 175.76M for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 175.76M |
| June 09, 2026 | 178.26M |
| June 08, 2026 | 159.76M |
| June 05, 2026 | 171.58M |
| June 04, 2026 | 173.95M |
| June 03, 2026 | 178.26M |
| June 02, 2026 | 194.60M |
| June 01, 2026 | 209.42M |
| May 29, 2026 | 207.05M |
| May 28, 2026 | 230.70M |
| May 27, 2026 | 381.46M |
| May 26, 2026 | 391.08M |
| May 22, 2026 | 383.91M |
| May 21, 2026 | 392.31M |
| May 20, 2026 | 357.70M |
| May 19, 2026 | 352.79M |
| May 18, 2026 | 371.22M |
| May 15, 2026 | 415.04M |
| May 14, 2026 | 432.45M |
| May 13, 2026 | 446.78M |
| May 12, 2026 | 439.21M |
| May 11, 2026 | 474.23M |
| May 08, 2026 | 433.68M |
| May 07, 2026 | 477.71M |
| May 06, 2026 | 484.87M |
| Date | Value |
|---|---|
| May 05, 2026 | 500.64M |
| May 04, 2026 | 525.63M |
| May 01, 2026 | 519.07M |
| April 30, 2026 | 487.74M |
| April 29, 2026 | 515.80M |
| April 28, 2026 | 482.11M |
| April 27, 2026 | 490.61M |
| April 24, 2026 | 503.92M |
| April 23, 2026 | 532.80M |
| April 22, 2026 | 552.66M |
| April 21, 2026 | 614.30M |
| April 20, 2026 | 646.86M |
| April 17, 2026 | 636.42M |
| April 16, 2026 | 557.67M |
| April 15, 2026 | 554.73M |
| April 14, 2026 | 577.07M |
| April 13, 2026 | 541.40M |
| April 10, 2026 | 629.39M |
| April 09, 2026 | 413.35M |
| April 08, 2026 | 307.21M |
| April 07, 2026 | 305.82M |
| April 06, 2026 | 309.58M |
| April 02, 2026 | 297.61M |
| April 01, 2026 | 287.60M |
| March 31, 2026 | 302.06M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.835B |
| Alnylam Pharmaceuticals, Inc. | 38.82B |
| Savara, Inc. | 870.39M |
| Vericel Corp. | 1.858B |
| Biogen, Inc. | 30.95B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.14M |
| Total Expenses (Quarterly) | 22.14M |
| EPS Diluted (Quarterly) | -1.241 |
| Earnings Yield | -29.71% |
| Normalized Earnings Yield | -29.71 |